Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE:BMY) revealed 9 unusual trades.

Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $545,670, and 5 were calls, valued at $215,825.

What's The Price Target?

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $52.5 for Bristol-Myers Squibb during the past quarter.

Analyzing Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Bristol-Myers Squibb's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Bristol-Myers Squibb's significant trades, within a strike price range of $35.0 to $52.5, over the past month.

Bristol-Myers Squibb 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

About Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Following our analysis of the options activities associated with Bristol-Myers Squibb, we pivot to a closer look at the company's own performance.

Bristol-Myers Squibb's Current Market Status

• Currently trading with a volume of 4,006,882, the BMY's price is down by -0.38%, now at $44.47.
• RSI readings suggest the stock is currently may be oversold.
• Anticipated earnings release is in 86 days.

What The Experts Say On Bristol-Myers Squibb

3 market experts have recently issued ratings for this stock, with a consensus target price of $47.666666666666664.

• Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Bristol-Myers Squibb, targeting a price of $52.
• Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Bristol-Myers Squibb with a target price of $43.
• Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Bristol-Myers Squibb with a target price of $48.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb with Benzinga Pro for real-time alerts.